Hyptolide Promotes Breast Cancer Stem Cells Apoptosis and S-phase Cell Cycle Arrest

Area of Science:

• Pharmacology
• Cancer Biology
• Natural Products Chemistry

Background:

• Breast cancer stem cells (BCSCs) exhibit resistance to apoptosis, contributing to chemotherapy failure and relapse.
• Targeting BCSCs is crucial for effective breast cancer treatment.
• Hyptolide, isolated from Hyptis pectinata, is investigated for its potential to overcome BCSCs-mediated chemoresistance.

Purpose of the Study:

• To evaluate the anti-cancer effects of hyptolide on BCSCs.
• To determine hyptolide's mechanism of action in inducing apoptosis in BCSCs.
• To identify molecular targets of hyptolide in BCSCs.

Main Methods:

• Cytotoxicity assessed via MTT assay.
• Apoptosis quantified using Annexin V/Propidium Iodide staining and flow cytometry.
• Cell cycle arrest analyzed by flow cytometry.
• Bioinformatic analysis identified molecular targets and pathways.

Main Results:

• Hyptolide demonstrated significant cytotoxic activity against BCSCs with an IC50 of 55 µg/mL.
• Apoptosis was induced in up to 32% of BCSCs in a dose-dependent manner.
• S-phase cell cycle arrest was observed, linked to the regulation of SRC, EGFR, and MAPK1 signaling pathways.

Conclusions:

• Hyptolide exhibits potential as a therapeutic agent for targeting BCSCs.
• The compound effectively induces apoptosis by modulating SRC, EGFR, and MAPK1 signaling.
• Further research into the molecular mechanisms is warranted for clinical development.